Stocks On the Move: Juniper Networks, Inc., Ciena Corporation, and Puma Biotechnology Inc

U.S. stocks are higher, following the European Central Bank's (ECB) stimulus announcement. Among specific equities in focus today are tech stocks Juniper Networks, Inc. (NYSE:JNPR) and Ciena Corporation (NYSE:CIEN), as well as drugmaker Puma Biotechnology Inc (NYSE:PBYI). Here's a quick roundup of what's moving JNPR, CIEN, and PBYI.

• JNPR is up 4.2% at $28.92, after some upbeat analyst attention. Instinet and Nomura both issued upgrades to "buy" from "neutral," and the latter hiked its price target to $33 from $24. JNPR has been on a steady track upwards since its post-earnings bull gap in October, and is set for its highest close of 2016 today. In the options pits, a fair number of bullish bettors are likely cheering today's price action, with Juniper Networks, Inc.'s 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) showing nearly 13 calls bought to open for every put over the last two weeks, a reading that sits in the 92nd percentile of its annual range. However, JNPR's option volume is relatively light on an absolute basis, with just 1,751 calls and 135 puts bought to open during that period.
  
  
• CIEN is up 13.8%, and is among the best performers on the New York Stock Exchange, as a record-high revenue and order backlog overshadow lackluster earnings. The stock notched a new annual high of $24.84 earlier today, and now sits above the $22-$23 range that has contained the shares since the beginning of the year. Bearish bettors may be sweating, with Ciena Corporation's 10-day put/call volume ratio at the ISE/CBOE/PHLX of 1.09 sitting higher than 93% of all other readings from the past 12 months. 

• PBYI is down 10.8% at $35.50 -- among the worst performers on the NYSE -- after delivering downbeat drug data last night, saying that its breast cancer drug, neratinib, may have a greater toxicity profile and more severe side effects than originally thought, which could jeopardize its eventual approval for patient use. PBYI has had a rough few months, with the shares tumbling more than 50% since their September highs, after an insider trading scandal. Today's price action may come as a surprise to near-term option players, with Puma Biotechnology Inc sporting a Schaeffer's put/call open interest ratio (SOIR) of 0.65, which sits lower than 91% of all other readings from the past year, indicating short-term speculators have been more call-skewed than usual.